Antitumor Efficacy of bcl-2 and c-myc Antisense Oligonucleotides in Combination with Cisplatin in Human Melanoma Xenografts: Relevance of the Administration Sequence

This publication has 23 references indexed in Scilit:

• Antisense oligodeoxynucleotides for urokinase‐plasminogen activator receptor have anti‐invasive and anti‐proliferative effects in vitro and inhibit spontaneous metastases of human melanoma in mice
  International Journal of Cancer, 2004
• Small Interfering RNA Targeting Bcl-2 Sensitizes Malignant Melanoma
  Oligonucleotides, 2003
• The future of antisense therapy: combination with anticancer treatments
  Oncogene, 2003
• Use of Oncogene Expression as an Independent Prognostic Marker for Primary Melanoma
  Annals of Plastic Surgery, 2003
• Tumor regression by combination antisense therapy against Plk1 and Bcl-2
  Oncogene, 2003
• Expression of Concern: Bcl‐2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF‐1mediated transcriptional activity
  The FASEB Journal, 2002
• The chemoresistance of human malignant melanoma
  Melanoma Research, 1999
• Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer
  Oncogene, 1998
• Bcl-2 expression in malignant melanoma and its prognostic significance
  European Journal of Surgical Oncology, 1996
• Phosphorothioate Oligodeoxynucleotides Bind to Basic Fibroblast Growth Factor, Inhibit Its Binding to Cell Surface Receptors, and Remove It from Low Affinity Binding Sites on Extracellular Matrix
  Published by Elsevier ,1995